लोड हो रहा है...
Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C
BACKGROUND: Combination therapy with pegylated interferon, ribavirin and a first-generation NS3/4A protease inhibitor, telaprevir or boceprevir, is the new strategy for treatment of genotype 1 chronic hepatitis C virus infection. This combination improves therapeutic efficacy but it also increases t...
में बचाया:
| में प्रकाशित: | J Dermatol Case Rep |
|---|---|
| मुख्य लेखकों: | , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Specjalisci Dermatolodzy
2014
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4299703/ https://ncbi.nlm.nih.gov/pubmed/25621089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3315/jdcr.2014.1183 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|